Want to track ANGO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 21 days
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
Benzinga | 1 year ago
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago.
Zacks | 1 year ago
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
